Sign in

    George Zavoico

    Research Analyst at Jones Trading

    George Zavoico is a Senior Equity Analyst specializing in life sciences and biotech sectors, with deep expertise covering companies such as Synergy Pharmaceuticals, Evoke Pharma, and CorMedix, particularly in the areas of biotechnology, biopharmaceuticals, and molecular diagnostics. He has earned recognition for his research performance, including multiple Financial Times/Starmine Awards for top-ranked earnings estimates in the biotechnology sector. Zavoico's career spans roles at B. Riley FBR, JonesTrading Institutional Services, MLV & Co., Cantor Fitzgerald, and Westport Capital Markets, following scientific and management roles in the pharmaceutical industry and nearly two decades as an analyst. He holds a Ph.D. in physiology, is FINRA registered, and has contributed numerous peer-reviewed publications in addition to his acclaimed equity research.

    George Zavoico's questions to OXGN leadership

    George Zavoico's questions to OXGN leadership • Q2 2015

    Question

    George Zavoico from Jones Trading inquired about the specifics of the upcoming AML trial for OXi4503, the focus of the Baylor University collaboration, and potential alternative funding strategies to mitigate risk.

    Answer

    President & CEO Bill Schwieterman detailed that the OXi4503 AML trial will target a broad refractory AML population, include a myelodysplastic syndrome (MDS) cohort, and is a combination study. He confirmed the Baylor collaboration is advancing promising early pipeline products. Regarding funding, Schwieterman and CFO Matt Loar affirmed they are exploring all options to preserve shareholder value, including non-traditional sources and partnerships, citing an existing trial where costs are shared.

    Ask Fintool Equity Research AI

    George Zavoico's questions to Oncotelic Therapeutics (OTLC) leadership

    George Zavoico's questions to Oncotelic Therapeutics (OTLC) leadership • Q1 2015

    Question

    George Zavoico of Jones Trading questioned how the evolving standard of care in ovarian cancer might influence the FDA's perspective on their planned Phase 3 trial. He also inquired about preclinical plans to explore combining their VDA technology with immunotherapies like checkpoint inhibitors.

    Answer

    President & CEO David Chaplin acknowledged that the changing treatment landscape is a factor in their ongoing discussions with the FDA and that they expect more clarity on the Phase 3 trial design by the end of the second quarter. He also confirmed that the company is actively planning preclinical studies to investigate the potential of combining their agents with immunotherapies, with studies expected to begin later in the year.

    Ask Fintool Equity Research AI

    George Zavoico's questions to Oncotelic Therapeutics (OTLC) leadership • Q4 2014

    Question

    George Zavoico of JonesTrading asked for clarification on the company's cash runway guidance through 2016, questioning what costs for the ovarian cancer Phase 3 trial were included. He also inquired about potential funding sources like partnerships and specifics of the trial design, such as patient inclusion criteria and the importance of PFS versus OS data.

    Answer

    CFO Barbara Riching clarified that the cash guidance through 2016 covers ongoing programs and planning for the ovarian trial, but not the full cost of conducting the Phase 3 study. CEO Dave Chaplin added that later-stage programs will require additional funding and confirmed they are open to various sources, including partnerships. He also noted that they are discussing trial design, including narrowing patient criteria, with KOLs and the FDA, and would proceed with a PFS endpoint if the FDA agrees, regardless of the OS data.

    Ask Fintool Equity Research AI